Search Result

Results for "

VEGFR-2 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	VEGFR (300) Akt (6) AMPK (1) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (2) Apoptosis (89) Aurora Kinase (5) Autophagy (39) Bacterial (4) Bcl-2 Family (4) Bcr-Abl (4) c-Fms (10) c-Kit (32) c-Met/HGFR (20) Carbonic Anhydrase (7) Casein Kinase (2) Caspase (3) CDK (7) Checkpoint Kinase (Chk) (1) Complement System (1) COX (1) Cytochrome P450 (2) Dihydrofolate reductase (DHFR) (2) Discoidin Domain Receptor (2) Drug Derivative (1) Drug Metabolite (1) EGFR (21) Endogenous Metabolite (3) Ephrin Receptor (1) ERK (5) FAK (2) Ferroptosis (8) FGFR (38) FLT3 (27) Fungal (2) GSK-3 (2) HDAC (4) HIF/HIF Prolyl-Hydroxylase (1) HSP (2) HSV (1) IKK (1) Insulin Receptor (2) Integrin (2) Interleukin Related (1) IRE1 (6) Isotope-Labeled Compounds (11) JAK (2) LRRK2 (1) MAP3K (1) MDM-2/p53 (5) MEK (2) Microtubule/Tubulin (4) Mitophagy (6) Mitosis (1) Mixed Lineage Kinase (2) mTOR (2) Necroptosis (3) NF-κB (2) p38 MAPK (1) Parasite (2) PDGFR (63) PERK (2) Phosphodiesterase (PDE) (1) PI3K (4) PROTACs (1) Raf (14) Ras (1) Reactive Oxygen Species (6) Reference Standards (2) RET (11) Src (17) STAT (4) Syk (1) TAM Receptor (9) Tie (9) Topoisomerase (2) Trk Receptor (4)
By Research Areas:	Cancer (295) Cardiovascular Disease (23) Endocrinology (1) Infection (7) Inflammation/Immunology (20) Metabolic Disease (4) Neurological Disease (2)

By Targets:

VEGFR (300)

Akt (6)

AMPK (1)

Anaplastic lymphoma kinase (ALK) (1)

Antibiotic (2)

Apoptosis (89)

Aurora Kinase (5)

Autophagy (39)

Bacterial (4)

Bcl-2 Family (4)

Bcr-Abl (4)

c-Fms (10)

c-Kit (32)

c-Met/HGFR (20)

Carbonic Anhydrase (7)

Casein Kinase (2)

Caspase (3)

CDK (7)

Checkpoint Kinase (Chk) (1)

Complement System (1)

COX (1)

Cytochrome P450 (2)

Dihydrofolate reductase (DHFR) (2)

Discoidin Domain Receptor (2)

Drug Derivative (1)

Drug Metabolite (1)

EGFR (21)

Endogenous Metabolite (3)

Ephrin Receptor (1)

ERK (5)

FAK (2)

Ferroptosis (8)

FGFR (38)

FLT3 (27)

Fungal (2)

GSK-3 (2)

HDAC (4)

HIF/HIF Prolyl-Hydroxylase (1)

HSP (2)

HSV (1)

IKK (1)

Insulin Receptor (2)

Integrin (2)

Interleukin Related (1)

IRE1 (6)

Isotope-Labeled Compounds (11)

JAK (2)

LRRK2 (1)

MAP3K (1)

MDM-2/p53 (5)

MEK (2)

Microtubule/Tubulin (4)

Mitophagy (6)

Mitosis (1)

Mixed Lineage Kinase (2)

mTOR (2)

Necroptosis (3)

NF-κB (2)

p38 MAPK (1)

Parasite (2)

PDGFR (63)

PERK (2)

Phosphodiesterase (PDE) (1)

PI3K (4)

PROTACs (1)

Raf (14)

Ras (1)

Reactive Oxygen Species (6)

Reference Standards (2)

RET (11)

Src (17)

STAT (4)

Syk (1)

TAM Receptor (9)

Tie (9)

Topoisomerase (2)

Trk Receptor (4)

By Research Areas:

Cancer (295)

Cardiovascular Disease (23)

Endocrinology (1)

Infection (7)

Inflammation/Immunology (20)

Metabolic Disease (4)

Neurological Disease (2)

332

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: VEGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103002

SU5408 4 Publications Verification VEGFR2 Kinase inhibitor I	VEGFR	Cardiovascular Disease
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent and cell-permeable inhibitor of *VEGFR2* kinase with an IC₅₀ of 70 nM.

HY-160259

VEGFR-2-IN-39	PROTACs VEGFR	Cardiovascular Disease
VEGFR-2-IN-39 (PROTAC-5) is a PROTAC targeting *VEGFR-2* (IC₅₀: 208.6 nM). VEGFR-2-IN-39 has low toxicity.VEGFR-2-IN-39 inhibits the proliferation of EA.hy926, one of HUVECs, in a concentration-dependent manner, with an IC₅₀ of 38.65 µM .

HY-168104

VEGFR-2-IN-55	VEGFR	Cancer
VEGFR-2-IN-55 (Compound 30) is a potent *VEGFR-2* kinase inhibitor with an IC₅₀ value of 1.24 nM . VEGFR-2-IN-55 has antitumor activity .

HY-13645

Henatinib	VEGFR c-Kit PDGFR	Cancer
Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities. Henatinib inhibits the activity of *VEGFR-2, c-kit, PDGFR* with IC₅₀ values of 0.6 nM, 3.3 nM and 41.5 nM, respectively. Henatinib significantly inhibits VEGFR-2 phosphorylation and its downstream signal pathway in human umbilical vein endothelial cells (HUVECs) .

HY-155760

hCA/VEGFR-2-IN-3	VEGFR Carbonic Anhydrase	Cancer
hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-3 inhibits VEGFR-2 (IC₅₀=358 nM), has high binding activity to hCAs with Ki of 4.2 nM (hCA IX), 22.9 nM (hCA II), 25.1 nM (hCA I), 28.0 nM (hCA XII), respectively. hCA/VEGFR-2-IN-3 has antiproliferative activity against VEGFR-2 overexpressing breast cancer cells .

HY-147694

c-Met-IN-11	c-Met/HGFR VEGFR	Cancer
c-Met-IN-11 (compound 3) is a potent c-MET and *VEGFR-2* inhibitor, with IC₅₀ values of 41.4 and 71.1 nM, respectively .

HY-155763

hCA/VEGFR-2-IN-4	VEGFR Carbonic Anhydrase	Cancer
hCA/VEGFR-2-IN-4 (compound 15b) is an indolinylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-4 inhibits VEGFR-2 (IC₅₀=0.811 μM) and has high binding activity to hCAs, with Ki of 3.8 nM (hCA XII), 6.2 nM (hCA IX), 19.8 nM (hCA II), and 35.5 nM (hCA I), respectively. hCA/VEGFR-2-IN-4 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells .

HY-155758

hCA/VEGFR-2-IN-2	VEGFR Carbonic Anhydrase	Cancer
hCA/VEGFR-2-IN-2 (compound 8g) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-2 inhibits VEGFR-2 (IC₅₀=204 nM) and has high binding activity to hCAs, with Kis of 3.6 nM (hCA IX), 16.1 nM (hCA II), 16.7 nM (hCA XII), and 75.3 nM (hCA I), respectively. hCA/VEGFR-2-IN-2 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells .

HY-155239

VEGFR-2-IN-35	VEGFR	Cancer
VEGFR-2-IN-35 (compound 7) is a potent VEGFR-2 inhibitor with IC₅₀=37 nM. VEGFR-2-IN-35 inhibits MCF-7 and HCT 116 cancer cells with IC₅₀ values of 10.56 and 7.07 μM, respectively .

HY-163747

VEGFR-2-IN-47	VEGFR	Cancer
VEGFR-2-IN-47 (compound 7g) is a potent *VEGFR-2* inhibitor with an IC₅₀ value of 0.072 µM. VEGFR-2-IN-47 can induce G2 / M phase cell cycle arrest, promote apoptosis, and boost immunomodulation by downregulating TNF-α expression and upregulating IL-2 levels in MCF-7 cells. VEGFR-2-IN-47 has the potential to be used for the research of cancer such as breast cancer and liver carcinoma .

HY-159510

VEGFR-2-IN-51	Apoptosis VEGFR Microtubule/Tubulin Reactive Oxygen Species	Cancer
VEGFR-2-IN-51 (compound 19) is an orally active dual-target inhibitor of *VEGFR-2* (IC₅₀=15.33 μM) and tubulin (IC₅₀=0.76 μM) with anti-tumor activity. VEGFR-2-IN-51 induces tumor cell apoptosis by reducing mitochondrial membrane potential and increasing reactive oxygen species (ROS) levels. VEGFR-2-IN-51 exerts anti-angiogenic effects by blocking the *VEGFR-2/PI3K/AKT* signaling pathway. In addition, VEGFR-2-IN-51 has significant anti-proliferative activity against the gastric cancer cell line MGC-803 (IC₅₀=0.005 μM) .

HY-169296

IMPDH2-IN-4	VEGFR CDK	Cancer
IMPDH2-IN-4 (compound 2d), a Mycophenolic acid (HY-B0421) analogue, is a selective IMPDH2 inhibitor with a K_i of 1.8 μM. IMPDH2-IN-4 exhibits good cytotoxic activity against osteosarcoma cancer cell lines. IMPDH2-IN-4 possesses a high affinity for VEGFR-2, CDK2, and IMPDH .

HY-145849

VEGFR2-IN-1	VEGFR	Cancer
VEGFR2-IN-1 is a potent and selective *VEGFR2* inhibitor (IC₅₀=19.8 nM). VEGFR2-IN-1 inhibits cell proliferation and migration through apoptosis activation and *VEGFR2* inhibition .

HY-18926

VEGFR2-IN-7	VEGFR	Cancer
VEGFR2-IN-7 (compound E) is an inhibitor of *VEGFR2. VEGFR2*-IN-7 can used in study cancers .

HY-147133

VEGFR2-IN-2	VEGFR	Cancer
VEGFR2-IN-2 (compound 6e) is a potent and selective *VEGFR2* inhibitor with an IC₅₀ of 19.32 nM. VEGFR2-IN-2 can be used for researching

HY-153158

VEGFR2-IN-3	VEGFR	Cancer
VEGFR2-IN-3 (compound 385) is a potent *VEGFR2* inhibitor .

HY-162326

VEGFR-2-IN-41	VEGFR Apoptosis	Cancer
VEGFR-2 IN-41 (Compound 8) is a *VEGFR-2* inhibitor with an IC₅₀ of 0.0554 μM. VEGFR-2 IN-41 can induce apoptosis. VEGFR-2-IN-41 has antitumor activity .

HY-149361

VEGFR2-IN-4	VEGFR	Inflammation/Immunology
VEGFR2-IN-4 (compound 25) is a potent and selective VEGFR2 kinase inhibitor, with a GI₅₀ of 0.7 nM. VEGFR2-IN-4 shows anti-angiogenic effect. VEGFR2-IN-4 can be used for the research of rheumatoid arthritis .

HY-168170

EGFR/VEGFR2-IN-2	VEGFR EGFR	Cancer
EGFR/VEGFR2-IN-2 (compound 4b) is an dual inhibitor *VEGFR-2* and *EGFR*. .

HY-149512

FGFR1/VEGFR2-IN-1	FGFR VEGFR	Cancer
FGFR1/VEGFR2-IN-1 (compound 2b) is an *FGFR1/VEGFR2* inhibitor. FGFR1/VEGFR2-IN-1 can be used for cancer research .

HY-147872

VEGFR-2-IN-22	VEGFR Microtubule/Tubulin Apoptosis	Cancer
VEGFR-2-IN-22 (Compound 25) is a dual *VEGFR-2* and β-tubulin polymerization inhibitor with an IC₅₀ of 19.82 nM against VEGFR-2. VEGFR-2-IN-22 induces apoptosis .

HY-P990106

Anti-Mouse VEGFR-2 Antibody (DC101)	VEGFR	Cancer
Anti-Mouse VEGFR-2 Antibody (DC101) is a potent *VEGFR2* inhibitor that can be used for the research of papilloma .

HY-168073

EGFR/VEGFR2-IN-1	EGFR VEGFR Apoptosis Microtubule/Tubulin	Cancer
EGFR/VEGFR2-IN-1 (Compound 10e) is a *VEGFR-2* and *EGFR* inhibitor (IC₅₀: 0.26 and 0.14 μM respectively). EGFR/VEGFR2-IN-1 inhibits tubulin polymerization with an IC₅₀ of 40.9 μM. EGFR/VEGFR2-IN-1 induces apoptosis. EGFR/VEGFR2-IN-1 can be used for research of antileukemia and antilymphoma .

HY-168655

EGFR/VEGFR2-IN-3	Apoptosis EGFR VEGFR	Cancer
EGFR/VEGFR2-IN-3 (compound 9) is a potent *EGFR* and *VEGFR-2* inhibitor with IC₅₀ values of 0.129, 0.142, 3.428 µM for EGFR, VEGFR-2, COX-2, respectively. EGFR/VEGFR2-IN-3 shows cytotoxicity. EGFR/VEGFR2-IN-3 induces apoptosis and cell cycle arrest at G2/M phase .

HY-168493

FLT3/VEGFR2-IN-1	FLT3 VEGFR HDAC STAT PERK	Cancer
FLT3/VEGFR2-IN-1 (Compound 26) is a *FLT3/VEGFR2/HDAC* inhibitor with IC₅₀ values of 14.5 nM, 3.9 nM, and 30.8 nM for FLT3, *VEGFR2, and HDAC1, respectively. FLT3/VEGFR2-IN-1 can inhibit* the phosphorylation of STAT3 and ERK1/2 and the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 has anti-tumor activity and can be used for the research of acute myeloid leukemia .

HY-148040

VEGFR-2-IN-29	VEGFR	Cancer
VEGFR-2-IN-29 (Compound 5) is a *VEGFR-2* inhibitor with an IC₅₀ of 16.5 nM .

HY-146539

HDAC-IN-35	HDAC VEGFR	Cancer
HDAC-IN-35 (Compound 14) is a potent, selective HDAC and *VEGFR-2* inhibitor, with IC₅₀ values of 0.166 and 13.2 µM for HDAC6 and *VEGFR-2*, respectively .

HY-P990147

Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a)	VEGFR	Others
Anti-Mouse VEGFR-2 Antibody (DC101-CP132) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse VEGFR-2.

HY-168597

FGFR1/VEGFR2-IN-3	FGFR Apoptosis VEGFR	Cancer
FGFR1/VEGFR2-IN-3 (Compound 8m) is a dual inhibitor of *FGFR1/VEGFR2. FGFR1/VEGFR2*-IN-3 exhibits anti-proliferative and anti-migratory activities against cancer cells, and is capable of inducing cell apoptosis .

HY-162887

VEGFR-2-IN-53	VEGFR Apoptosis	Cancer
VEGFR-2-IN-53 (Compound 15w) is a *VEGFR-2* inhibitor with an IC₅₀ of 4.34 μM. VEGFR-2-IN-53 induces apoptosis by inhibiting *VEGFR-2* activity and preventing cell migration, thereby exhibiting anti-angiogenic effects. The IC₅₀ value of VEGFR-2-IN-53 for inhibiting MCF-7 cell growth is 3.87 μM. VEGFR-2-IN-53 can be used in cancer research .

HY-172179

EGFR/VEGFR2-IN-5	EGFR VEGFR	Cancer
EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of *EGFR* and *VEGFR2* with an IC₅₀ value of 1.15 µM for *VEGFR2* and an IC₅₀ value of 0.28 μM for EGFR ^T790M. EGFR/VEGFR2-IN-5 has significant anticancer activity .

HY-163471

PDGFRα/β/VEGFR-2-IN-1	PDGFR VEGFR	Cancer
PDGFRα/β/VEGFR-2-IN-1 (6f), a multiple PDGFRα/ and *VEGFR-2* tyrosine kinase inhibitor, particularly targets PDGFRα, PDGFRβ, and VEGFR-2 kinases with Nano molar concentrations .

HY-109020

Acrizanib 1 Publications Verification LHA510	VEGFR	Others
Acrizanib (LHA510) is a *VEGFR-2* inhibitor, with an IC₅₀ of 17.4 nM for BaF3-VEGFR-2 .

HY-10368

EGFR/VEGFR2-IN-4	EGFR VEGFR	Cancer
EGFR/VEGFR2-IN-4 (Compound 19) is the irreversible inhibitor for *EGFR* and *VEGFR-2* with IC₅₀ of 18.7 nM and 102.3 nM, under the presence of 1 μM ATP .

HY-100419

BFH772	VEGFR	Cancer
BFH772 is a potent oral *VEGFR2* inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC₅₀ value of 3 nM .

HY-168126

VEGFR-2-IN-56	VEGFR	Cancer
VEGFR-2-IN-56 (compund 12e) is a potent *VEGFR-2* inhibitor (IC₅₀=45.9 nM) .

HY-12018

Vatalanib dihydrochloride 10+ Cited Publications PTK787 dihydrochloride; ZK-222584 dihydrochloride; CGP-797870 dihydrochloride	VEGFR Apoptosis	Cancer
Vatalanib dihydrochloride (PTK787 dihydrochloride) is an inhibitor of *VEGFR2/KDR* with IC₅₀ of 37 nM.

HY-144804

VEGFR-2-IN-17	VEGFR	Cancer
VEGFR-2-IN-17 (Compound 15a) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 67.25 nM. VEGFR-2-IN-17 shows antitumor activities .

HY-149630

VEGFR2/HDAC1-IN-1	VEGFR HDAC Apoptosis	Cancer
VEGFR2/HDAC1-IN-1 (compound 13) is a potent *VEGFR-2/HDAC* dual inhibitor, with IC₅₀s of 57.83 nM and 9.82 nM, respectively. VEGFR2/HDAC1-IN-1 arrests the cell cycle at the S and G2 phases, and induces apoptosis in HeLa cells. VEGFR2/HDAC1-IN-1 exhibits anti-angiogenic effect .

HY-169516

VEGFR-2-IN-65	VEGFR	Cancer
VEGFR-2-IN-65 (Compound 07) is a *VEGFR-2* inhibitor. VEGFR-2-IN-65 has H-bond interactions with Cys180. VEGFR-2-IN-65 inhibits tube formation in HUVECs .

HY-168435

VEGFR-2-IN-63	VEGFR	Cancer
VEGFR-2-IN-63 (Compound 12b) is the inhibitor for *VEGFR2* that inhibits 87.2% VEGFR-2 at 10 μM. VEGFR-2-IN-63 exhibits antiproliferative activity in multiple cancer cell, IC₅₀s for HCT116, MCF7 and PaCa2 is 6.5 μM, 2.1 μM and 4.1 μM, respectively .

HY-144803

VEGFR-2-IN-16	VEGFR	Cancer
VEGFR-2-IN-16 (Compound 15b) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 86.36 nM. VEGFR-2-IN-16 shows antitumor activities .

HY-147902

VEGFR-2-IN-24	VEGFR	Cancer
VEGFR-2-IN-24 is a potent *VEGFR-2* inhibitor with IC₅₀ value of 0.22 µM. VEGFR-2-IN-24 can be used for tumor research .

HY-162509

YS07	VEGFR	Cancer
YS07 is a potent *VEGFR-2* inhibitor. Molecular dynamics simulation study revealed sustained interactions of YS07 with key amino acids of VEGFR-2 at a run time of 100 ns. YS07 can be used for anticancer research .

HY-18625

VEGFR-2-IN-5	VEGFR	Cancer
VEGFR-2-IN-5 is a *VEGFR2* inhibitor extracted from patent WO2013055780A1, Page 69 .

HY-18625A

VEGFR-2-IN-5 hydrochloride	VEGFR	Cancer
VEGFR-2-IN-5 hydrochloride is a *VEGFR2* inhibitor extracted from patent WO2013055780A1, Page 69 .

HY-147800

VEGFR-2-IN-21	VEGFR	Cancer
VEGFR-2-IN-21 (Compound 5d) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 0.10 μM. VEGFR-2-IN-21 shows anticancer activity .

HY-146236

VEGFR-2-IN-27	VEGFR	Cancer
VEGFR-2-IN-27 (compound 7a) is a highly potent *VEGFR-2* inhibitor with an IC₅₀ value of 14.8 nM. VEGFR-2-IN-27 can be used for researching anticancer .

HY-146492

VEGFR-2/BRAF-IN-2	VEGFR Raf Apoptosis	Cancer
VEGFR-2/BRAF-IN-2 (Compound 4a) is a dual *VEGFR-2* and BRAF kinases inhibitor with IC₅₀ values of 0.111, 0.089 and 0.071 µM against VEGFR-2, BRAF ^V600E and BRAF ^WT, respectively. VEGFR-2/BRAF-IN-2 induces apoptosis and arrests the cell cycle mainly in the G1 phase .

HY-19624

NVP-ACC789 ACC-789; ZK202650	VEGFR PDGFR	Cancer
NVP-ACC789 is an inhibitor of human *VEGFR-1, VEGFR-2* (mouse *VEGFR-2), VEGFR-3* and PDGFR-β with IC₅₀s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.

Cat. No.	Product Name	Type

HY-10407G

SU 5402 (GMP)	Fluorescent Dye
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for *VEGFR2, FGFR1, and PDGFRβ*, respectively .

Cat. No.	Product Name	Type

HY-10407G

SU 5402 (GMP)	Biochemical Assay Reagents
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for *VEGFR2, FGFR1, and PDGFRβ*, respectively .

Cat. No.	Product Name	Target	Research Area

HY-P1663

ATWLPPR Peptide 1 Publications Verification	VEGFR	Others
ATWLPPR Peptide is a biological active peptide. (This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.)

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-P5910

Azurin p28 peptide	MDM-2/p53 Apoptosis	Cancer
Azurin p28 peptide is a tumor-penetrated antitumor peptide. Azurin p28 peptide redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide induces apoptosis or cell cycle arrest. Azurin p28 peptide inhibits p53-positive tumor growths. Azurin p28 peptide shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .

HY-P10833

C-VGB3	VEGFR PI3K Akt mTOR ERK Apoptosis	Cardiovascular Disease Cancer
C-VGB3 is a selective vascular endothelial growth factor receptor 2 (VEGFR2) antagonist, which inhibits VEGFR2-mediated PI3K/AKT/mTOR and PLCγ/ERK1/2 signaling pathways. C-VGB3 binds to the extracellular domain of VEGFR2, blocking ligand-receptor interaction and inducing apoptosis in endothelial and tumor cells through both intrinsic (involving Bcl2 family and caspases) and extrinsic (death receptor-mediated) pathways. C-VGB3 is promising for research of angiogenesis-related cancers, such as breast cancer .

HY-P3990

Coibamide A	VEGFR Autophagy Apoptosis	Cancer
Coibamide A, an N-methyl-stabilized cytotoxic depsipeptide, shows potent antiproliferative activity. Coibamide A induces autophagosome accumulation via an mTOR-independent mechanism. Coibamide A induces apoptosis. Coibamide A inhibits *VEGFA/VEGFR2* expression and suppresses tumor growth in glioblastoma xenografts .

HY-P5910A

Azurin p28 peptide TFA	MDM-2/p53 Apoptosis	Cancer
Azurin p28 peptide TFA is a tumor-penetrated antitumor peptide. Azurin p28 peptide TFA redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide TFA induces apoptosis or cell cycle arrest. Azurin p28 peptide TFA inhibits p53-positive tumor growths. Azurin p28 peptide TFA shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .

Cat. No.	Product Name	Target	Research Area

HY-P990106

Anti-Mouse VEGFR-2 Antibody (DC101)	VEGFR	Cancer
Anti-Mouse VEGFR-2 Antibody (DC101) is a potent *VEGFR2* inhibitor that can be used for the research of papilloma .

HY-P9920A

Ramucirumab (anti-VEGFR)	VEGFR	Cancer
Ramucirumab (anti-VEGFR) is a human *VEGFR-2* antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .

HY-P99830

Conbercept KH902	VEGFR	Cardiovascular Disease
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a vascular endothelial growth factor (VEGF) inhibitor .

HY-P99768

Olinvacimab TTAC-0001	VEGFR	Cancer
Olinvacimab (TTAC-0001) is a fully human *anti-VEGFR2* monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a K_d value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .

HY-108801A

Aflibercept (VEGF Trap) 1 Publications Verification	VEGFR	Cardiovascular Disease Metabolic Disease Cancer
Aflibercept (VEGF Trap) is a soluble decoy *VEGFR* constructed by fusing the Ig domains of *VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits* VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-P990147

Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a)	VEGFR	Others
Anti-Mouse VEGFR-2 Antibody (DC101-CP132) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse VEGFR-2.

HY-P991132

Efclarofusp alfa	VEGFR	Cardiovascular Disease Cancer
Efclarofusp alfa is a CHO-expressed humanized antibody consisting of *VEGFR-1* and *VEGFR-2* regions fused to human IgG1 Fc. Efclarofusp alfa is an angiogenesis inhibitor .

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease Cancer
Aflibercept (VEGF Trap) is a soluble decoy *VEGFR* constructed by fusing the Ig domains of *VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits* VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0883

Gamabufotalin 4 Publications Verification Gamabufagin	Structural Classification Animals Classification of Application Fields Source classification Disease Research Fields Steroids Cancer	VEGFR
Gamabufotalin (Gamabufagin), a main active compound isolated from Chinese medicine Chansu, has been shown to strongly inhibit cancer cell growth and inflammatory response. Gamabufotalin could inhibite angiogenesis by inhibiting the activation of VEGFR-2 signaling pathways.

HY-12686

5Z-7-Oxozeaenol Maximum Cited Publications 23 Publications Verification FR148083; L783279; LL-Z 1640-2	Structural Classification Natural Products Monophenols Microorganisms Classification of Application Fields Source classification Phenols Inflammation/Immunology Disease Research Fields	MAP3K VEGFR Antibiotic
5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and *VEGF-R2, with IC₅₀*s of 8 nM and 52 nM, respectively.

HY-112234

L-Sepiapterin Sepiapterin	Alkaloids Structural Classification Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
L-Sepiapterin (Sepiapterin) is a precursor of the endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (BH4). L-Sepiapterin improves endothelial dysfunction in small mesenteric arteries from db/db mice, and induces angiogenesis. L-Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70 ^S6K-dependent VEGFR-2 expression .

HY-107417

Hypothemycin	Structural Classification Monophenols Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Phenols Disease Research Disease Research Fields Cancer	VEGFR MEK FLT3 PDGFR ERK
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively .

HY-N2666

5α-Hydroxycostic acid	Other Terpenoids Classification of Application Fields Terpenoids Source classification Erythrina burttii Baker f. Plants Compositae Disease Research Fields Cancer	VEGFR
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating *VEGF/VEGFR2* and Ang2/Tie2 pathways .

HY-N0563

Alizarin 1 Publications Verification	Quinones Structural Classification Classification of Application Fields Anthraquinones Source classification Rubiaceae Other Diseases Phenols Polyphenols Plants Disease Research Fields Rubia cordifolia L.	AMPK VEGFR PI3K Akt NF-κB Cytochrome P450
Alizarin is a natural dye. Alizarin can be extracted from the roots of madder plant. Alizarin activates AMPK and *VEGFR2/eNOS* pathway. Alizarin regulates PI3K/Akt and inhibits NF-κB pathway. Alizarin enhances CYP1A1 enzyme activity. Alizarin has protective effects on hypertension and vascular endothelial dysfunction. Alizarin has anti-tumor activity against multiple cancers including pancreatic cancer, breast cancer, osteosarcoma and liver cancer. Alizarin has been widely used as a pigment in textile fabrics and paintings .

HY-N3127

Orobol	Flavonoids Classification of Application Fields Leguminosae Glycine max (L.) merr Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Isoflavones	Casein Kinase PI3K VEGFR
Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC₅₀=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC₅₀=3.46-5.27 μM for PI3K α/β/γ/K/δ) .

HY-N8342

Rhamnazin	Structural Classification Combretaceae Source classification Phenols Polyphenols Plants Combretum erythrophyllum Sond.	VEGFR
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC₅₀ of 4.68 μM against *VEGFR2* kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy . Rhamnazin shows antioxidant and anti-inflammatory properties .

HY-152120

(±)-Aiphanol Aiphanol	Structural Classification Source classification Phenols Polyphenols Arecaceae Plants Aiphanes aculeata Willd	COX VEGFR
(±)-Aiphanol is a newly discovered stilbenolignan analog. (±)-Aiphanol exhibits significant anti-inflammatory activity, acting through inhibition of COX-1 and COX-2. The inhibitory effect on COX-1 (IC₅₀ = 1.9 μM) is particularly strong, while the effect on COX-2 (IC₅₀= 9.9 μM) is relatively weak .(±)-Aiphanol effectively inhibits *VEGFR2* (IC₅₀=0.92 μM). (±)-Aiphanol blocks angiogenesis and promotes apoptosis through inhibition of VEGFR2 and COX2 activity. (±)-Aiphanol is orally active .

HY-W011873R

Palmitoleic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
Pazopanib (Hydrochloride) (Standard) is the analytical standard of Pazopanib (Hydrochloride). This product is intended for research and analytical applications. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-Y0121

Ethyl cinnamate	Structural Classification Kaempferia galanga L. Microorganisms Classification of Application Fields Source classification Other Diseases Other Phenylpropanoids Phenylpropanoids Plants Disease Research Fields Zingiberaceae	Parasite VEGFR Apoptosis
Ethyl cinnamate, an orally active chemical constituent of the rhizome of Kaempferia galanga, exhibits anti-cancer, nematocidal, sedative and vasorelaxant activities. Ethyl cinnamate is a fragrance ingredient used as a food flavor and additive for cosmetic products. Ethyl cinnamate is also an excellent clearing reagent for mammalian tissues. Ethyl cinnamate suppresses tumor growth through anti-angiogenesis by attenuating *VEGFR2* signal pathway in colorectal cancer. Ethyl cinnamate inhibits the tonic contractions induced by high K+ and phenylephrine (PE) with respective IC₅₀ values of 0.30 mM and 0.38 mM in rat aorta .

HY-Y0121R

Ethyl cinnamate (Standard)	Structural Classification Kaempferia galanga L. Microorganisms Source classification Other Phenylpropanoids Phenylpropanoids Plants Zingiberaceae	Parasite VEGFR Apoptosis
Ethyl cinnamate (Standard) is the analytical standard of Ethyl cinnamate. This product is intended for research and analytical applications. Ethyl cinnamate, an orally active chemical constituent of the rhizome of Kaempferia galanga, exhibits anti-cancer, nematocidal, sedative and vasorelaxant activities. Ethyl cinnamate is a fragrance ingredient used as a food flavor and additive for cosmetic products. Ethyl cinnamate is also an excellent clearing reagent for mammalian tissues. Ethyl cinnamate suppresses tumor growth through anti-angiogenesis by attenuating VEGFR2 signal pathway in colorectal cancer. Ethyl cinnamate inhibits the tonic contractions induced by high K+ and phenylephrine (PE) with respective IC₅₀ values of 0.30 mM and 0.38 mM in rat aorta .

Cat. No.	Product Name	Chemical Structure

HY-13342AS

Apatinib-d8 free base

Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base . Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC₅₀=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC₅₀s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ .

HY-15992S

BIBF 1202-13C,d3
BIBF 1202- ¹³C,d₃ is the ¹³C- and deuterium labeled BIBF 1202. BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM.

HY-10255AS

Sunitinib-d10
Sunitinib-d₁₀ is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively .

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-10260S

Vandetanib-d6
Vandetanib-d₆ is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC₅₀=110 nM) and EGFR/HER1 (IC₅₀=500 nM) .

HY-10260S1

Vandetanib-d4
Vandetanib-d₄ is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC₅₀=110 nM) and EGFR/HER1 (IC₅₀=500 nM) .

HY-10255AS1

Sunitinib-d4
Sunitinib-d₄ is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively .

HY-10260S2

Vandetanib-13C6
Vandetanib- ¹³C₆ is a ¹³C labeled Vandetanib (HY-10260) . Vandetanib (D6474) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

HY-12047S

Ponatinib-d8
Ponatinib-d₈ is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-10208S

Pazopanib-d6
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10065S1

Axitinib-d3
Axitinib-d₃ (AG-013736-d₃) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively .

HY-10065S

Axitinib-13C,d3
Axitinib- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC₅₀ values of 0.1, 0.2, 0.1-0.3, 1.6 nM for *VEGFR1, VEGFR2, VEGFR3* and PDGFRβ, respectively .

HY-12009S

Pazopanib-13C,d3 hydrochloride
Pazopanib- ¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride . Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively .

HY-W705479

Pazopanib-d3 hydrochloride
Pazopanib-d₃ (hydrochloride) (GW786034-d₃ (hydrochloride)) is deuterium labeled Pazopanib (Hydrochloride). Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of *VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms* with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-W758126

(R)-Brivanib alaninate-d4
(R)-Brivanib alaninate-d₄ is the deuterium-labeled Brivanib (alaninate) (HY-10336). Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against *VEGFR2* with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ .

HY-10208S1

Pazopanib-13C,d3
Pazopanib- ¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib . Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively .

HY-10208S2

Pazopanib-d3
Pazopanib-d₃ (GW786034-d₃) is deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of *VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms* with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively .

HY-10201S2

Sorafenib-13C,d3

1 Publications Verification

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-10201S4

Sorafenib-d3 tosylate

Sorafenib-d₃ (Donafenib-d₃) tosylate is the deuterium labeled Sorafenib (HY-10201). Sorafenib is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib-d3tosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib-d3tosylate induces autophagy and apoptosis. Sorafenib-d3tosylate has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-Y0121S1

Ethyl cinnamate-d7

Ethyl cinnamate-d₇ is deuterated labeled Ethyl cinnamate (HY-Y0121). Ethyl cinnamate, an orally active chemical constituent of the rhizome of Kaempferia galanga, exhibits anti-cancer, nematocidal, sedative and vasorelaxant activities. Ethyl cinnamate is a fragrance ingredient used as a food flavor and additive for cosmetic products. Ethyl cinnamate is also an excellent clearing reagent for mammalian tissues. Ethyl cinnamate suppresses tumor growth through anti-angiogenesis by attenuating VEGFR2 signal pathway in colorectal cancer. Ethyl cinnamate inhibits the tonic contractions induced by high K+ and phenylephrine (PE) with respective IC50 values of 0.30 mM and 0.38 mM in rat aorta .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks